Shein A.M.S.Wannigama D.L.Hurst C.Monk P.N.Amarasiri M.Badavath V.N.Phattharapornjaroen P.Ditcham W.G.F.Ounjai P.Saethang T.Chantaravisoot N.Thuptimdang W.Luk-in S.Nilgate S.Rirerm U.Tanasatitchai C.Kueakulpattana N.Laowansiri M.Liao T.Kupwiwat R.Rojanathanes R.Ngamwongsatit N.Thammahong A.Ishikawa H.Pletzer D.Leelahavanichkul A.Ragupathi N.K.D.Wapeesittipan P.Ali Hosseini Rad S.M.Kanjanabuch T.Storer R.J.Miyanaga K.Cui L.Hamamoto H.Higgins P.G.Kicic A.Chatsuwan T.Hongsing P.Abe S.Mahidol University2023-11-042023-11-042023-12-01Biomedicine and Pharmacotherapy Vol.168 (2023)07533322https://repository.li.mahidol.ac.th/handle/20.500.14594/90925Given the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration. Recently, adjuvants like CaEDTA have shown the ability to enhance the effectiveness of combined antimicrobial agents. Here, we tested a phage-adjuvant combination and demonstrated the effectiveness of intranasally inhaled phage (KKP10) + CaEDTA in addition to ceftazidime/avibactam (CZA) for chronic P. aeruginosa lung infections. The results emphasize that intranasal inhalation of phage along with CaEDTA can successfully re-sensitize MDR P. aeruginosa to CZA in a triple combination treatment. This promising approach shows potential as a therapy for chronic respiratory tract infections.Pharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1016/j.biopha.2023.1157932-s2.0-8517503039019506007